43,787 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Turtle Creek Wealth Advisors LLC

Turtle Creek Wealth Advisors LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 43,787 shares of the company’s stock, valued at approximately $3,218,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Banque Transatlantique SA purchased a new position in AstraZeneca during the fourth quarter worth $26,000. Confluence Investment Management LLC purchased a new position in AstraZeneca during the first quarter worth $27,000. Mascagni Wealth Management Inc. purchased a new position in AstraZeneca during the fourth quarter worth $29,000. FNY Investment Advisers LLC purchased a new position in AstraZeneca during the first quarter worth $29,000. Finally, Highline Wealth Partners LLC increased its position in AstraZeneca by 447.4% during the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock worth $31,000 after buying an additional 340 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday. BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price target for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.00.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $71.13 on Monday. The company has a market cap of $220.60 billion, a P/E ratio of 28.57, a P/E/G ratio of 1.31 and a beta of 0.37. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The business has a fifty day simple moving average of $70.72 and a 200-day simple moving average of $70.84.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.06 earnings per share. Equities research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.